This site is intended for healthcare professionals
ACARE podcast hero
All Things Angioedema and Urticaria: Podcasts
Declaration of sponsorship GA²LEN UCARE/ACARE

All Things Angioedema

Declaration of sponsorship GA²LEN UCARE/ACARE
Last updated:8th Apr 2024
Published:28th Feb 2024

Join Dr Thomas Buttgereit, dermatologist and allergist at the Angioedema Center of Reference and Excellence (ACARE), Berlin, and other experts in this podcast series to hear the latest news and views in hereditary angioedema (HAE).

A new episode is published every 2 weeks as part of the ACARE LevelUp Educational Program.

Please provide feedback and offer your suggestions for future topics and expert selection here

Complete feedback form

Episode 16 – ACE inhibitor-induced angioedema

Ear, nose and throat specialist Dr Robin Lochbaum joins Dr Thomas Buttgereit to discuss angiotensin-converting enzyme (ACE) inhibitor‑induced angioedema, including information on the incidence and mechanism of action, and antihypertensive treatment options.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Concomitant medication in patients with bradykinin-mediated angioedema – there’s more than ACE inhibitors; The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema; and Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors – a nationwide registry-based cohort study.

Episode 15 – Mast cell-mediated angioedema

“Should it be considered a part of chronic spontaneous urticaria?” Dr Thomas Buttgereit welcomes Dr Marta Ferrer Puga to talk about mast cell-mediated angioedema, including discussion of the international urticaria guidelines definition.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: A comparative study of sex distribution, autoimmunity, blood, and inflammatory parameters in chronic spontaneous urticaria with angioedema and chronic histaminergic angioedema; Angioedema severity and impact on quality of life: Chronic histaminergic angioedema versus chronic spontaneous urticaria; and Medical algorithm: Diagnosis and management of histaminergic angioedema.

Episode 14 – Collaboration in HAE

“There are a lot of doctors that should know about angioedema.” Ear, nose and throat specialist Dr Janina Hahn joins Dr Thomas Buttgereit to discuss the importance of implementing an interdisciplinary approach in HAE, including tips on overcoming challenges.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/.

Episode 13 – Angioedema in the paediatric population

“Children should be informed about their illness according to their age.” Professor Henriette Farkas joins Dr Thomas Buttgereit to discuss angioedema in children, covering acute treatment options and the differing symptoms between adults and children.  

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Results from the phase 3 SPRING study; International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency; and Diagnosing pediatric patients with hereditary C1-inhibitor deficiency.

Episode 12 – The HAE specialist: ‘Never give up’

“I want to take an extra step, just to make sure that we never give up and provide them with the care that they deserve to receive.” Dr Danny Cohn joins Dr Thomas Buttgereit to talk about the role of an HAE specialist providing long-term, often multigenerational care, including the benefits offered by ACARE centres.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: The Chronic Urticaria Registry (CURE).

Episode 11 – The perspective from India in treating paediatric patients 

Dr Thomas Buttgereit is joined by Professor Ankur Kumar Jindal to discuss his experience as a paediatrician treating angioedema in India, covering the reoccurring challenges and how best to counsel families when discussing the risk of transmission to the next generation.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: P-49 Transmission patterns in C1-INH deficiency Hereditary Angioedema favours a wild-type male offspring: our experience at Chandigarh, India; Management of hereditary angioedema in resource-constrained settings: A consensus statement from Indian subcontinent; Screening for type II hereditary angioedema; Transmission patterns of C1-INH deficiency hereditary angioedema favours a wild-type male offspring and Epidemiology, management and treatment access of hereditary angioedema in the Asia pacific region.

Episode 10 – Who is behind the scenes of ACARE?

Dr Thomas Buttgereit is joined by Julia Föll and Reinhardt Britz to discuss the responsibilities of working within an ACARE office, covering audit criteria and ongoing ACARE projects.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Become an ACARE, ACARE LevelUp: The ACARE physician information and education platform and Programme for the identification of mutations in genes of patients with recurrent idiopathic or hereditary angioedema.

Episode 9 – The AURORA study

“In the past, they’ve used 72 different combinations of outcomes and outcome measures.” Remy Peterson joins Dr Thomas Buttgereit to discuss the need for the AURORA study, and shares the resulting consensus for acute treatment outcomes in HAE.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/.

Additional resources relating to the topics discussed in this episode can be found here: The registered study protocol: AcUte tReatment Outcomes in heReditary Angioedema (AURORA) and Outcome measures in randomized controlled studies of acute therapy for hereditary angioedema: A systematic review.

Episode 8 – The future of angioedema: Is there a cure on the horizon? 

Join Dr Lauré Fijen and Dr Thomas Buttgereit as they discuss emerging angioedema treatments, covering efficacy, safety, frequency and route of administration. The experts also reflect on the possibility of a cure for HAE.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Hereditary angioedema: The clinical picture of excessive contact activation and Current and prospective targets of pharmacologic treatment of hereditary angioedema types 1 and 2.

Episode 7 – Treating hereditary angioedema

Join Professor Anna Valerieva and Dr Thomas Buttgereit as they discuss the burden of living with rare forms of angioedema, particularly HAE. Drawing from her expertise as an allergologist at the Medical University of Sofia, Bulgaria, Professor Valerieva emphasises the importance of viewing patients holistically and considering their preferences. The experts also review how the introduction of new treatments has changed patients’ lives and minimised recurrent angioedema attacks.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Mitigating disparity in healthcare resources between countries for management of hereditary angioedema and Therapeutic management of hereditary angioedema: past, present, and future.

Episode 6 – Tackling acquired angioedema and related comorbidities

Join Dr Andrea Zanichelli and Dr Thomas Buttgereit as they discuss complex angioedema cases, including acquired angioedema diagnosed in later life. Drawing from his perspective as Head of the Angioedema Center in Milan, Italy, Dr Zanichelli explores how C1 and C4 inhibitor deficiencies may indicate a possible acquired angioedema diagnosis, common comorbidities due to this condition, and the current treatment options available.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency, A nationwide study of acquired C1-inhibitor deficiency in France: characteristics and treatment responses in 92 patients, Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study, Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship and Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization.

Episode 5 – An ENT view of angioedema

Join Dr Antonia Scherer and Dr Thomas Buttgereit as they discuss the impact of recurrent hereditary angioedema on the larynx. Drawing from her perspective as an ENT expert, Dr Scherer explores how laryngeal angioedema is assessed in the clinic, and the current treatment options available.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update and Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency

Episode 4 – Androgens in hereditary angioedema

Dr Thomas Buttgereit is joined by Dr Carolina Vera to discuss the use of attenuated androgens in the treatment of hereditary angioedema and their associated risks and side effects. Both exerts delve into the safety, ethical considerations and alternative treatment options to using androgens for the treatment of hereditary angioedema. Dr Vera concludes the discussion with an in-depth explanation of the SHAERPA project, focusing on the discontinuation of androgen use in individuals with angioedema, and the benefits this project can have in providing guidance on alternative medications.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update, Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series and WAO Guideline for the Management of Hereditary Angioedema.

Episode 3 – Angioedema and EAACI 2023

Professor Jason Fok joins Dr Thomas Buttgereit to discuss angioedema updates from the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2023 and the role EAACI has in disseminating novel insights in angioedema treatment and diagnosis. Dr Buttgereit takes a deep dive into how data presented at EAACI congresses can be implemented into specialist ACARE clinics and the benefits the congress has in aiding clinicians to implement the latest guidelines for the benefit of patients.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Biomarkers in hereditary angioedema, Managing diagnosis, treatment, and burden of disease in hereditary angioedema patients with normal C1-esterase inhibitor, The expanding spectrum of mutations in hereditary angioedema, and Recurrent angioedema: Diagnosing the rare and the frequent.

Episode 2 – What is angioedema and what is not?

Dr Thomas Buttgereit is joined by Professor Markus Magerl, leader of the angioedema clinics at ACARE Berlin. Their conversation explores the clinical features of recurrent angioedema and the essential differential diagnoses that dermatologists must bear in mind when encountering facial swellings.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group.

Episode 1 – What “angioedemologists” do and what motivates them

Dr Thomas Buttgereit welcomes the renowned urticaria specialist, Professor Marcus Maurer. Professor Maurer is the founding force behind both ACARE and UCARE, and spearheads the popular podcast, All Things Urticaria. The pair delve into the significance of angioedema across all areas of medicine and offer insights into the role and responsibilities of angioedemologists. They also shed light on the complexities of tackling angioedema, highlighting the invaluable role of the ACARE global network in tackling these challenges.

For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence.

Meet the host

Professor Christopher Edwards.jpg

Thomas Buttgereit, MD

Thomas Buttgereit is a dermatologist and allergist at the Angioedema Center of Reference and Excellence (ACARE) Berlin. He regularly gives consultations for patients with different types of recurrent angioedema including patients with HAE. His special interests are clinical and basic research on mast cell-mediated angioedema, HAE due to C1 inhibitor (C1INH) deficiency and HAE with normal C1INH.

Disclosures: Thomas Buttgereit is or recently was a speaker and/or advisor for AstraZeneca, BioCryst, CSL-Behring, GSK, Hexal, KalVista, Medac, Novartis, Pharming, Roche, Sanofi, and Takeda.

These podcasts are brought to you by the ACARE network. The ACARE program, initiated by GA2LEN and HAE International, aims to establish and accredit a network of angioedema centres. The purpose of this collaborative network is to enhance angioedema care and research, in order to improve patient outcomes.

Welcome: